Introduction
Conditionally replicating adenoviruses (CRAds) represent a promising approach for treating cancer refractory to traditional therapies. 1 Recently, it has been demonstrated that the oncolytic potency of virotherapy with replicating agents is partly determined by their capability of infecting target cells. 2, 3 Most adenovirus vectors and CRAds are based on serotype 5 (Ad5), which binds to the coxsackie-adenovirus receptor (CAR). Unfortunately, recent data suggest variable CAR expression on ovarian and some other cancer cells, which could hinder CRAd-mediated oncolysis in these cancer cells. 4 Therefore, methods to circumvent CAR deficiency have been evaluated. Previously, we evaluated a serotype chimeric Ad5/3 adenovirus possessing the receptor-binding fiber knob domain of Ad3 in the Ad5 capsid, which retargeted the virus to the Ad3 receptor highly expressed on ovarian and other cancer cells. 5, 6 Recently, it has been suggested that there is a common receptor for subgroup B adenoviruses, which Ad3 also belongs to. 7 Specifically, the CD46 membrane cofactor protein has been proposed. 8, 9 In contrast, a recent publication suggests that Ad3 does not use CD46 as an attachment receptor. 9 CD46 is a member of a family of glycoproteins acting as regulators of complement activation, and therefore prevents spontaneous activation of complement on autologous cells. Interestingly, also CD80 and CD86 costimulatory molecules have been proposed as candidate Ad3 receptors. 10 As Ad5/3 chimerism increased gene delivery to tumor but not normal cells, we created an Ad3 receptor retargeted CRAd, Ad5/3-D24. 3 This oncolytic virus has a 24-bp deletion in E1A, resulting in a mutant E1A protein unable to bind in the Rb protein, which normally allows S-phase entry, needed for virus replication. Therefore, Ad5/3-D24 replicates in cancer cells inactive in the Rb/p16 pathway, 11 including most if not all human cancer cells. 12 Ad5/3-D24 displayed enhanced oncolytic potency and therapeutic efficacy in ovarian cancer models as compared to an otherwise isogenic CRAd, but with the wild-type fibers.
Although the safety data with CRAds in clinical trials have been excellent, not much is known about persistence or antitumor activity, as there is a paucity of means for detecting these agents in vivo. 4 Nevertheless, noninvasive methods for obtaining safety and efficacy information on experimental therapy approaches both in orthotopic animal models and in humans could be conducive for the rapid development of novel treatment approaches for cancer refractory to currently available modalities. As both safety and efficacy relate to persistence and propagation of the treatment agent, a secretory marker protein whose expression correlates with replication might allow noninvasive detection of these variables. Trackable proteins have been evaluated in the context of oncolytic measles viruses. The results with the soluble extracellular domain of human carcinoembryogenic antigen (hCEA)-expressing measles viruses have been promising in vitro and in vivo.
13,14 Thus, we sought to test the approach in the setting of replicating adenoviruses. Therefore, we constructed Ad5/3-D24-hCEA, which features the hCEA gene in the E3A region under the control of an endogenous replication-coupled gene expression system. We hypothesize that, during virus replication, soluble hCEA glycoprotein is expressed in parallel with the E3A region proteins, and that hCEA could be measured in plasma. Most epithelial ovarian cancers do not express hCEA, 15, 16 which might make this trackable glycoprotein useful for monitoring ovarian cancer virotherapy.
Our aims were to establish a correlation between viral replication and hCEA blood concentration and between hCEA blood concentration and tumor response. Another possible approach for analyzing efficacy and tumor response noninvasively could be in vivo imaging. In our orthotopic ovarian cancer animal model using in vivo bioluminescence imaging, we were able to detect intraperitoneal (i.p.) tumor cell killing by the virus. Furthermore, measuring plasma hCEA allowed correlation of the secretory marker to in vivo efficacy.
Results
Generation and characterization of Ad5/3-D24-hCEA The 2 kb gene encoding hCEA was inserted in 6.7K/ gp19K-deleted E3A region of Ad5/3-D24 resulting in Ad5/3-D24-hCEA, where the endogenous viral E3A gene expression control elements, that is, promoter and polyadenylation signals, are used for controlling the expression of soluble hCEA. The control virus, Ad5/3-D24DE3, has the E3 region deleted (Figure 1a) . To characterize the virus in vitro, we analyzed replication with quantitative PCR for the E4 gene, and concomitantly measured the hCEA levels in growth medium by ELISA. To show that replication of Ad5/3-D24-hCEA causes increasing hCEA concentration in growth medium over a period of time (120 h), we infected monolayers of SKOV3.ip1 cells with one viral particle (vp)/ cell, and analyzed the virus copy numbers and hCEA levels at indicated time points (Figure 1b) . We found an exponential correlation R 2 ¼ 0.8591 between the virus copies and hCEA in a scatter plot. Importantly, samples collected at 6 h showed that the mere internalization of the virus prior to replication does not result in hCEA secretion. Further, in comparison to virus DNA replication, the secretion of hCEA was delayed with circa 20 h. The non-hCEA-secreting oncolytic virus was included as a control to confirm that the replication of adenovirus or subsequent cell lysis per se is not the reason for hCEA production. Also, this allowed us to evaluate whether the replicative potency of Ad5/3-D24-hCEA was compromised due to hCEA secretion. Despite the plateau late during the infection, correlation between the replication curves was good (R 2 ¼ 0.8937 in a scatter plot). For testing the effect of the virus dose on hCEA secretion, SKOV3.ip1 cells were infected with increasing amounts of Ad5/3-D24-hCEA, and E4 copy number and hCEA were determined 24 h later (Figure 1c) . We found an increase in hCEA secretion, which correlated with the Increase in virus copy number and hCEA levels over 5 days. Cells were infected with 1 vp/cell, and at the indicated time points cells were harvested and Ad5/3-D24-hCEA (') copy number was analyzed by quantitative PCR. Corresponding hCEA (J) levels were measured from growth medium. Replication of Ad5/3-D24-hCEA was compared to Ad5/3-D24DE3 (&). The study was performed in triplicates, and a trendline R 2 was analyzed on scatter plot. (c) Correlation between virus dose and soluble hCEA levels in growth medium. Cells were infected with increasing amounts of virus. After 24 h, Ad5/3-D24-hCEA copies (') and hCEA (J) levels were analyzed as above in quadruplicates.
Dual-modality monitoring of adenovirus replication
A Kanerva et al replication of Ad5/3-D24-hCEA in a dose-dependent manner (exponential trendline, R 2 ¼ 0.8023).
Plasma hCEA profile in an orthotopic ovarian cancer model
The therapeutic efficacy of Ad5/3-D24-hCEA was tested in an i.p. model of disseminated ovarian cancer. Advanced carcinomatosis was allowed to develop and then mice were treated with Ad5/3-D24-hCEA, Ad5/3-D24DE3 or no virus on three consecutive days (7, 8, and 9) and later, on day 33, with one more injection. Plasma hCEA was analyzed weekly for all the mice (Figure 2 ). Two out of 10 Ad5/3-D24-hCEA-treated mice showed plasma hCEA responses, that is, an increase after virus injection and subsequent decrease. Further, they also responded to the latter injection on day 33 (Figure 2a, b) .
Four out of 10 mice demonstrated significant early response as above, but later the hCEA concentration showed continuous increase, suggesting continuous virus replication (Figure 2c-f) . Finally, there was a group of mice, which displayed a rapid increase in plasma hCEA levels during the last 7 days, while the initial response was comparable to the other groups (Figure 2g j). Importantly, none of the analyzed mice treated with a control virus Ad5/3-D24DE3 had measurable hCEA concentrations in plasma. The median survival of mice treated with Ad5/3-D24-hCEA or Ad5/3-D24DE3 was not reached, and all the Ad5/3-D24-hCEA-treated mice were alive in the end of the experiment on day 59 ( Figure  2k ). Residual i.p. tumors were harvested and virus copies were measured with quantitative PCR. All of the Ad5/3-D24-hCEA-treated mice had residual tumors showing 3 Â 10 4 -2 Â 10 6 E4 copies per ng of cellular b-actin, which suggested virus replication. The survival of mice treated with the Ad5/3-D24DE3 control was 70714.5% (versus Ad5/3-D24-hCEA, P ¼ 0.083). Three out of 10 mice in this group died on day 20 due to anesthesia complications, Figure 2 hCEA levels in vivo after i.p. injection of the viruses on days 7, 8, 9, and 33 in i.p. tumor-bearing mice. (a, b) Two mice out of 10 displayed responses to virus injection, reflected as an increase in hCEA levels after both virus cycles, followed by rapid decrease. (c-f) Four mice had an initial response as seen in an early increase and then followed by decrease of hCEA levels. However, later on, the hCEA levels increased again without any decrease reflecting continued replication. (g-j) Persistent production of hCEA with a strong increase towards the end of the experiment, suggesting late replication of the virus. (k) Survival of the mice treated with Ad5/3-D24-hCEA, Ad5/3-D24DE3 or no virus. *Three mice died on day 20 due to anesthesia complications.
Dual-modality monitoring of adenovirus replication A Kanerva et al but the remaining mice survived to the end of the experiment, and only four of them had residual i.p. tumor. Again, virus was detected in the tumors at high levels, copy numbers ranging from 3 Â 10 4 to 3 Â 10
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. For the untreated group, the median survival of mice was 31 days. In comparison to the untreated mice, the overall survival of mice treated with Ad5/3-D24-hCEA was improved (log-rank test Po0.0001).
Dual-modality in vivo monitoring of Ad5/3-D24-hCEAtreated mice
The efficacy of Ad5/3-D24-hCEA was also evaluated with quantitative, noninvasive in vivo imaging. Firefly luciferase-expressing SKOV3-luc cells were injected i.p. (day 0), followed by an injection of Ad5/3-D24-hCEA or no virus on days 7, 8, 9, and 28. Bioluminescence imaging can be performed noninvasively subsequent to i.p. injection of D-luciferin, and the photon counts correlate with tumor size 3 ( Figure 3 ). The level of emitted light in the Ad5/3-D24-hCEA-treated group did not increase during the experiment; instead, it was reduced by 61% on day 35 (Figure 3b ). However, the difference was not significant, and within the treatment group there were no significant differences in mean photon count at any time point versus baseline on day 7. However, the untreated mice emitted significantly more light over the time period. On day 35, photon counts had increased up to 131-fold (P ¼ 0.0082, as compared to day 7). Light emitted from the peritoneal cavity of Ad5/3-D24-hCEA-treated mice was only 0.35% of the signal of the untreated group on day 35 (P ¼ 0.0097). Results of the repeated measures model showed a significant group n time effect (P ¼ 0.0069) indicating an overall increase in amount of emitted light over time in the untreated group compared to the Ad5/3-D24-hCEA group. The individual comparisons between groups at each time point reached significance at day 28 (P ¼ 0.0112) and day 35 (P ¼ 0.0097) indicating divergence of the tumor growth lines and therefore therapeutic efficacy. The correlation between tumor killing as measured by emitted light and plasma hCEA levels was also analyzed in three mice (Figure 3c ). One of them responded partially, showing an initial increase in hCEA, followed by a decrease in emitted light. However, eventually, the tumor relapsed as detected with bioluminescence. Interestingly, virus replication also concomitantly increased. Two mice displayed an initial peak in replication, that is, an increase in hCEA, and a subsequent peak in bioluminescence. Afterwards, there was no significant residual light emitted, suggesting tumor eradication, and also plasma hCEA was low, reflecting the absence of virus replication. Thus, tumor eradication was achieved in these two mice as measured by dual modality in vivo monitoring.
Serum hCEA profile and concurrent virus replication in subcutaneous (s.c.) tumors
The correlation between Ad5/3-D24-hCEA replication and hCEA blood concentration was tested in an s.c. model of ovarian cancer. Ovarian adenocarcinoma Hey cell tumors were established into both flanks of the nude mice. Tumors were injected intratumorally with Ad5/3-D24-hCEA, Ad5/3-D24 or no virus on days 10 and 14. Thereafter, on days 17, 20, and 24 from two to four mice/ group were analyzed for serum hCEA levels and the tumors were tittered for infectious viral particles. The amount of infectious viral particles was approximately one order of magnitude lower in the tumors injected with Ad5/3-D24-hCEA. However, both CRAds displayed replication in the s.c. tumors (Figure 4a) . None of the mice treated with control virus (Ad5/3-D24) or no virus displayed any hCEA in serum. In contrast, hCEA levels of the Ad5/3-D24-hCEA-treated mice correlated with the virus yield of the s.c. tumors (linear trendline,
Discussion
This study demonstrates that expression of a soluble marker protein, hCEA, from an adenovirus genome, allows noninvasive in vivo monitoring of virus persistence. Further, this transgene does not seem to significantly affect the replication kinetics of the virus. We Dual-modality monitoring of adenovirus replication A Kanerva et al utilized the endogenous adenoviral gene expression machinery for the control of hCEA production, by removing 965-bp from E3A, which resulted in a 6.7K/ gp19K-deleted genome, and inserted the transgene in this deletion. The E3 region of adenovirus is an early transcription unit encoding at least seven proteins. Interestingly, the E3 region is nonessential for viral replication, but the E3 proteins have an important role in the regulation of host immune response. Specifically, they inhibit both innate and specific immune responses. Further, it is known that deletion of the E3 region results in increased lymphocyte, macrophage, and monocyte inflammatory responses (reviewed in Horwitz et al 17 ) . gp19K binds and sequesters major histocompatibility complex I (MHC I) molecules in the endoplasmic reticulum, and therefore prevents the recognition of infected cells by cytotoxic Tlymphocytes (CTLs). 17 This reduces CTL-mediated cytolysis of infected cells. Interestingly, this is another feature shared between the adenovirus life cycle and carcinogenesis, as also tumor cells can evade CTL lysis with various methods. Thus, a gp19K-deleted virus, such as ours, might allow infection and subsequent productive replication preferentially in tumor cells, as infected normal cells would be effectively recognized by CTLs. This could provide an additional level of selectivity, in addition to the 24-bp deletion in E1A, which restricts virus replication to Rb/p16 pathway-deficient cells. In essence, we have developed a triple-targeted virus, as the chimeric capsid facilitates entry into ovarian cancer cells.
Another protein deleted in our construct is 6.7K, which is expressed on cellular surface. It induces, as a complex with other E3 proteins, downregulation of TNFrelated apoptosis inducing ligand (TRAIL) receptor 2.
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Lack of this protein could further restrict replication of the virus in normal cells. The 6.7K/gp19K deletion has been demonstrated to allow effective expression of the remaining E3 and structural proteins. 19 The adenoviral death protein (ADP) is immediately 3 0 from the 965-bp deletion. This protein is expressed later during the virus cycle, and it contributes to cell lysis and release of virus progeny. 17 Downstream from ADP are the E3B genes encoding the receptor internalization and degradation (RID)-a/b complex, which protects the infected cells from lysis by various proapoptotic ligands such as FasL and TNF by internalizing their receptors, and by promoting degradation in the lysosymes. Further, the RID complex reduces arachidonic acid production. Also, the 14.7K protein has similar effects. 17, 18 All the E3B proteins inhibit inflammation after adenovirus infection in vivo. Importantly, by creating a partial deletion, we may be able to enhance the selectivity of replication while retaining functions that are conducive for effective oncolysis, such as ADP expression.
While there are antiadenovirus antibodies in many patients, it has been shown that modification of adenovirus capsid allows partial escape from preexisting neutralizing antibodies. We have shown that this is particularly true for Ad5/3 chimeric viruses. 6 Most importantly, adenovirus vectors and CRAds have been evaluated for safety and efficacy in more than 120 phase I/II cancer trials with more than 700 patients, and the safety profile has been excellent. 4 Finally, the oncolytic mechanism for adenovirus has been intricately evaluated and utilized for treatment of patients, in the context of CRAds. Therefore, we sought to evaluate the secretory marker approach in the context of CRAds. To render the marker secretory, we utilized hCEA lacking the hydrophobic C-terminus, which anchors the glycoprotein to the cell membrane. hCEA is a 180 kDa glycoprotein, which is expressed by many cancers. Some patients with mucinous ovarian cancer or with recurring or stage III disease have detectable levels of hCEA in serum. 15, 16 However, most epithelial ovarian cancers do not express hCEA. Several possible functions have been suggested for the membrane-bound form of hCEA. It plays a role in cell adhesion, might inhibit cell differentiation, and promotes entering G 0 phase. 20 It is not known whether secreted hCEA has a biological function, but it is widely used as a routine clinical marker, which facilitates possible clinical utilization.
In this study, we saw correlation between Ad5/3-D24-hCEA replication and hCEA production in vitro ( Figure  1) . Further, the 2 kb transgene did not affect replication significantly as compared to an E3 deleted control. Despite the plateau late during the infection, correlation between the replication curves was good. This plateau might be related to either reduced or delayed expression of E3 proteins and structural proteins due to a partial deletion and a transgene. Of note, the control virus utilized in this experiment has the complete E3 region deleted. Therefore, the plateau should not be E3 protein related. However, Hawkins et al 19 showed that the 6.7K/ gp19K-deleted virus has the fiber expression similar to the wild-type virus. Thus, the expression of soluble hCEA might affect the replication kinetics. Dual-modality monitoring of adenovirus replication A Kanerva et al Importantly, we were able to follow the virus kinetics in vivo in i.p. tumor-bearing mice (Figure 2 ). All mice treated with Ad5/3-D24-hCEA survived the whole duration of the experiment, while all untreated mice died due to progressive carcinomatosis. However, none of the mice were tumor free on day 59 at the end of the experiment. Nevertheless, most of them displayed increases in plasma concentration of hCEA after each virus injection, suggesting productive replication and concomitant antitumor efficacy. Further, some of them had high plasma hCEA levels during the last week of the experiment, suggesting strong replication. Therefore, it seems possible that a balance between virus replication and tumor cell growth was achieved. Alternatively, it may be possible that, although few tumor cells were remaining, they had gained resistance to oncolysis but continued to allow Ad5/3-D24-hCEA DNA replication and subsequent hCEA expression. Interestingly, although episomal persistence of adenoviral DNA has been reported, 21 our results suggest that, in some cases, tumor cells can acquire resistance to CR2-mutated CRAds. This has not been demonstrated before, and therefore highlights the usefulness of markers of virus persistence for understanding and evaluating the efficacy of virotherapy.
Considering that SCID mice were studied, the result may have been different if the immune system was intact, and CTLs would be available for clearing the infected cells. 17 Of note, virus was replicating in each of the tumors as measured with hCEA or quantitative PCR of harvested tumors, and all the mice survived to the end of the experiment. Thus, Ad5/3-D24-hCEA is oncolytic, and delivers a therapeutic effect, which may nonetheless be slightly weaker than what we have seen with the parent virus, Ad5/3-D24, in earlier studies. 3 However, human trials would be needed to demonstrate if there is difference in clinical efficacy or safety.
Imaging techniques can provide fundamental safety, efficacy, and virus replication information on CRAd therapies in orthotopic animal models. Further, another important feature of noninvasive imaging is the possibility of performing repeated and longitudinal measurements. 22 We used optical charge-coupled device (CCD) imaging to detect in vivo bioluminescence emitted from D-luciferin reacting with tumor cell-expressed firefly luciferase. Therefore, oncolytic killing of tumor cells corresponds with reduction of signal in comparison to control animals. 3 To correlate hCEA secretion with antitumor efficacy, we used dual modality monitoring, that is, simultaneous in vivo imaging and measurement of plasma hCEA concentrations (Figure 3) . On day 35, light emitted from the peritoneal cavity of Ad5/3-D24-hCEA-treated mice was only 0.35% of the untreated group, suggesting effective killing of tumor cells by the virus. In the treated animals, emitted light decreased, while in the untreated mice, a significant increase was seen. Concomitant analysis of hCEA levels suggested strong early replication, when the tumors were larger. Then, 2 weeks later, the replication was already slowing down, but the photon count was at its highest. Finally, both values decreased to baseline in two out of three mice. This suggests that hCEA secretion was primarily an early event and at its maximum during the intratumoral and i.p. dissemination of the virus, while the actual dying of the cells was a slower process during which bioluminescent imaging was still possible. Thus, such dual-modality methodology may allow an insight into the in vivo dynamics and kinetics of oncolysis.
Oncolytic viruses expressing trackable marker proteins might represent a new generation of antitumor agents, which can be dynamically monitored. These would be highly useful tools for evaluating the replication, persistence, and efficacy of the viruses. Further, such agents might provide a useful parameter for dose escalation purposes in clinical trials. The main advantage of this methodology is its flexibility and low cost compared to nuclear medicine imaging (PET, SPECT), which can provide accurate spacio-temporal measurements. To further increase the monitoring capacity of this CRAd, a transgene allowing in vivo imaging might be interesting. Various imaging systems have been evaluated. 22, 23 For example, expression of somatostatin receptor subtype 2, coded by an adenovirus vector, can be imaged with radioisotope gamma camera after administration of the somatostatin analogue 99m Tc-P2045. Other approaches include magnetic resonance and PET imaging of positron-emitting ligands such as imaging of sodium/iodide symporter (NIS), herpes simplex type 1 thymidine kinase (HSV-TK), and dopamine receptor D2. Also, in an animal model, an enhanced green fluorescent protein expressed in parallel with virus replication could prove practical by facilitating fluorescence in vivo imaging in combination with detection of the soluble marker. Thus, these imaging methods would further improve noninvasive monitoring of the localization and magnitude of replication and persistence.
In conclusion, we have demonstrated that a soluble marker protein expressed from a selectively oncolytic adenovirus can be measured in growth medium or plasma. Further, this allowed us to follow the persistence and antitumor efficacy of the virus in vivo. Finally, we compared the replication kinetics to tumor eradication evaluated by in vivo imaging. These developments could be useful for monitoring CRAd replication in humans, which might increase the quantity and quality of correlative data obtained in early-phase cancer gene therapy trials. This, in turn, might facilitate the bench-tobedside-and-back translational process and eventually make novel treatments available to patients more rapidly. 
Materials and methods

Construction of adenoviruses
A pAdEasy-1-derived plasmid containing a chimeric 5/3 fiber, pAdEasy-1.5/3, was created by homologous recombination in Escherichia coli of Ad5/3luc1 5 viral (Figure 1a) . In order to insert hCEA gene into E3 region, the method described in Hawkins et al 19 was used. Briefly, SpeI (27082) to NdeI (31089) fragment from Ad5 genome was inserted into the multi-cloning site of pGEM5Zf+ (Promega, Madison, WI, USA) resulting in a plasmid pTHSN, which was further digested with SunI/MunI, creating a 965-bp deletion in the E3 region (6.7K and gp19K deleted). cDNA encoding the extracellular domain of hCEA (2031 bp) was amplified by mutagenic PCR generating SunI/MunI restriction enzymes sites flanking the gene (CEA(S): 5 0 -ACGTCGTACGATGGAGTCTCC CTCGGCCCCT-3 0 , CEA(AS): 5 0 -TGTGCAATTGCTATG CAGAGACTGTGATGCTCTTG-3 0 ) and then inserted into SunI/MunI-digested pTHSN. pAdEasy-1.5/3-D24-hCEA was generated by homologous recombination in E. coli between FspI-linearized pTHSN-hCEA and SrfIlinearized pAdEasy-1.5/3-D24. Ad5/3-D24-hCEA was rescued as above ( Figure 1a) . As an additional control virus, previously described Ad5/3-D24 containing the intact E3 region was utilized. 3 For all viruses, the presence of the 24-bp deletion in E1A and the Ad3 knob in the fiber was confirmed with PCR as described. 3 Also, the absence of the wild-type E1A in both viruses and the absence of the E3 region in Ad5-D24DE3 were analyzed with PCR. 3 Further, hCEA insert and about 700 bp flanking it on both sides were sequences. Viruses were propagated on A549 cells, and purified on cesium chloride gradients. The vp concentration was determined at 260 nm, and standard plaque assay on 293 cells was performed to determine infectious particles. The ratios of vp/infectious particles were 63, 5.6, and 13.5 for Ad5/3-D24-hCEA, Ad5/3-D24DE3, and Ad5/3-D24, respectively.
In vitro growth kinetics of Ad5/3-D24-hCEA Cells in triplicate wells in 24-well plate were infected with 1 vp/cell of Ad5/3-D24-hCEA or Ad5/3-D24DE3 for 1 h at 371C in 200 ml of growth medium with 2% FBS. Cells were washed once, and 1 ml of 5% growth medium was added. At the indicated time points (6, 24, 48, 72, 96 , 120 h post-infection) supernatant was collected, and hCEA level was measured as described. 13 Cells were trypsinized and DNA was purified with a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA), and the total E4 copy number and human b-actin were quantitated as described. 3 The human b-actin is an endogenous cellular gene which exhibits relatively constant expression level. In the protocol, we make a standard curve of 200, 20, 2, and 0.2 ng of b-actin to quantify the amount of DNA of analyzed samples. In order to measure the virus replication after infection with increasing virus doses, cells in quadruplicate in 24-well plate were infected with 0/1/10/100/1000 or 10 000 vp/cell of Ad5/3-D24-hCEA for 1 h at 371C in 200 ml of growth medium with 2% FBS. Thereafter, cells were incubated with 10% growth medium for 24 h. hCEA level and E4 copy number were analyzed as above. SKOV3.ip1 cells on day 0. On days 7, 8, 9, and 33 mice were injected i.p. with 1 Â 10 8 vp of Ad5/3-D24-hCEA (n ¼ 10 mice), Ad5/3-D24DE3 (n ¼ 10) or no virus (n ¼ 5) in 1 ml of Opti-MEM (Mediatech, Herndon, VA, USA). Anesthetized (ketamine 100 mg/kg and xylazine 15 mg/ kg i.p. in 100 ml of PBS) mice were bled weekly into heparinized tubes to obtain plasma samples for hCEA analysis. Mice were followed daily and killed when there was any evidence of pain or distress. On day 59, surviving mice were killed, and residual tumors were harvested. Thereafter, DNA was purified using a DNeasy Tissue Kit (Qiagen), and quantitative PCR for E4 copies was performed as above. Survival analyses were conducted by using the Kaplan-Meier product limit methods and the comparison between groups by the log-rank procedure (SAS s v.9.0, SAS Institute, Cary, NY, USA). P-value of o0.05 was deemed statistically significant.
Plasma hCEA profile and concurrent in vivo bioluminescence imaging
The i.p. tumors were established by injecting 10 7 SKOV3-luc cells i.p. into female CB17 SCID mice (Charles River Laboratories, Wilmington, MA, USA) on day 0. On days 7, 8, 9 and 28, 1 Â 10 8 vp of Ad5/3-D24-hCEA (n ¼ 3) or no virus (n ¼ 4) were injected i.p. in a 1 ml volume of Opti-MEM. Imaging was performed before treatment on day 7 and then weekly using imaging method described earlier. 3 For comparison of tumor size with bioluminescence data, we constructed a repeated-measures linear model that tested for the effects of time, treatment group, and the interaction of treatment group and time on emitted light. For comparison of mean tumor bioluminescence within each treatment group at days 14, 21, 28, and 35 with baseline (day 7), we used the Wilcoxon-rank sum test (SAS s v.9.0, SAS Institute). P-value of o0.05 was deemed statistically significant. Weekly plasma samples were harvested and analyzed as above.
Correlation of serum hCEA levels and virus replication in s.c. tumors
Female athymic NMRI CD-1 nude mice (Taconic, Valburg, The Netherlands) were injected in both flanks with 5 Â 10 6 Hey human ovarian adenocarcinoma cells s.c. and tumors were allowed to grow. Mice received two intratumoral injections of 5 Â 10 7 vp of Ad5/3-D24-hCEA or Ad5/3-D24 (n ¼ 8 mice, 16 tumors) or no virus (n ¼ 2 mice, four tumors) days 10 and 14 after cell inoculation. On days 17, 20, and 24, blood samples were harvested via tail vein, and the hCEA level was analyzed from serum as above in the laboratory of the Department of Obstetrics and Gynecology, Helsinki University Central Hospital. Further, two to four mice/group were killed at each time point by cardiac puncture, and the s.c. tumors
Dual-modality monitoring of adenovirus replication A Kanerva et al were harvested, weighed, and snap frozen. After gradual thaw on ice, the tumors were minced into small pieces using scalpels, and subsequently freeze-thawed three times in DMEM. After centrifugation, the supernatant was tittered on A549 cells by modified TCID 50 assay. Of note, one mouse was analyzed for the CPE and the background hCEA expression before receiving any treatment.
